Johnson & Johnson 2Q profit jumps 42% despite lower sales
The maker of baby shampoo and cancer and immune disorder drugs on Tuesday raised its full-year sales forecast, despite sharply lower sales from its medical device business.
Canadian class action launched over J&J’s baby powder
Suit against Johnson & Johnson’s Canadian subsidiary involves alleged link to ovarian cancer.
Johnson & Johnson recalls 32M contraceptive packages outside US
Company has yet to resolve problems related to quality control and plant upgrades, says University of Michigan pharmaceuticals analyst.